KRAS and neoplasm: As a result, in August 2009, NICE (UK) approved the use of cetuximab in combination with either FOLFOX or FOLFIRI for patients presenting with liver-only metastases from KRAS wild-type tumours, where the metastases were not amenable to surgical resection and could not be sufficiently downstaged with initial chemotherapy.